Ming‐Feng Hou

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text

Breast Oncology, Long-term Effects, Medicine +7

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng et al. · Journal of Clinical Oncology · 2020 · 588 citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Wild-type p53 upregulates an early onset breast cancer-associated gene GAS7 to suppress metastasis via GAS7–CYFIP1-mediated signaling pathway

Jer-Wei Chang, Wen‐Hung Kuo, Chiao-Mei Lin et al. · Oncogene · 2018 · 536 citations · Full text

Breast Oncology, Gas7 Gene Expression, Cancer Biology +20

Deregulated expression of the PER1 , PER2 and PER3 genes in breast cancers

Shou‐Tung Chen, Kong‐Bung Choo, Ming‐Feng Hou et al. · Carcinogenesis · 2005 · 417 citations